Three-year outcomes of the RESILIENT trial: are they enough to support a primary stenting policy?
Department of Cardiovascular Surgery, Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, Texas 77030, USA. MDavies@tmhs.org
Mark G
MG
Davies
D000497:Alloys; D000800:Angioplasty, Balloon / Q000295:instrumentation*; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D005260:Female; D005263:Femoral Artery; D006801:Humans; D007383:Intermittent Claudication / Q000628:therapy*; D008297:Male; D011150:Popliteal Artery; D015607:Stents
D000497:Alloys; C013616:nitinol